Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV in Chinese patients
NCT00952341Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Aug 2009; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00952341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952341.